Clostridioides Difficile Infection Clinical Trial
Official title:
The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
Verified date | July 2023 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This research is being done to study the ability of C. difficile to colonize the colonic mucosa of individuals with no prior history of C. difficile infection.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 23, 2020 |
Est. primary completion date | December 23, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults aged 18 and over - No history of C. difficile infection - Undergoing clinically indicated colonoscopy for colon cancer screening or colon polyp surveillance purposes in the absence of active GI symptoms. Exclusion Criteria: - Known active pregnancy - Other known active gastrointestinal infectious process - Inflammatory gastrointestinal conditions (microscopic colitis, inflammatory bowel disease, Celiac disease) - Vulnerable adults - Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence of C. difficile within the sigmoid colonic mucosal tissue | C. difficile identified on fluorescence microscopy via FISH staining | 1 day (At time of biopsy) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03895593 -
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
|
||
Withdrawn |
NCT04679324 -
The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
|
||
Completed |
NCT04675723 -
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
|
||
Recruiting |
NCT05693077 -
Clostridioides Difficile Colonisation
|
Phase 1 | |
Completed |
NCT03183141 -
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
Recruiting |
NCT05709184 -
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
|
N/A | |
Terminated |
NCT05526807 -
Ursodeoxycholic Acid in C. Difficile Infection
|
N/A | |
Recruiting |
NCT06306014 -
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06237452 -
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
Terminated |
NCT04802837 -
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
|
Phase 3 | |
Active, not recruiting |
NCT04885946 -
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
|
N/A | |
Recruiting |
NCT04305769 -
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
|
Phase 2 | |
Recruiting |
NCT06106698 -
Washed Microbiota Transplantation for Clostridioides Difficile Infection
|
||
Active, not recruiting |
NCT04781387 -
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
|
Phase 2 | |
Completed |
NCT03595566 -
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
|
Phase 3 | |
Completed |
NCT03595553 -
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
|
Phase 3 | |
Completed |
NCT04725123 -
Addressing Personalized Needs in Clostridioides Difficile Infection
|
N/A | |
Not yet recruiting |
NCT05852587 -
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
|
Phase 1 | |
Completed |
NCT03788434 -
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 2 | |
Recruiting |
NCT05612672 -
Evaluation of GeoHAI Implementation
|
N/A |